Drug intelligence / Profile preview

KT-100

Development stage: Unknown
Lead developer: Kinoxis Therapeutics
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

KT-100 is a recombinant canine interferon-gamma, a veterinary drug developed for the treatment of atopic dermatitis in dogs. Clinical trials have demonstrated its efficacy in reducing symptoms such as pruritus, excoriation, erythema, and alopecia in affected animals.

Targets

IFNGR1 (Interferon gamma receptor 1)

Beyond the preview

Go deeper on KT-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT-100.

Explore the full profile